Who are Bivalirudin with and without eptifibatide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bivalirudin-with-and-without-eptifibatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Bivalirudin with and without eptifibatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bivalirudin with and without eptifibatide (Bivalirudin with and without eptifibatide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide). Area: Cardiovascular.

marketed Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bivalirudin with and without eptifibatide (Bivalirudin with and without eptifibatide) — LifeBridge Health. Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bivalirudin with and without eptifibatide TARGET	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) class)

LifeBridge Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bivalirudin with and without eptifibatide — Competitive Intelligence Brief. https://druglandscape.com/ci/bivalirudin-with-and-without-eptifibatide. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab